SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
BioMedReports FDA Calendar: Swine Flu Trial Set to Begin
NVS
|
|
|
+19.69%
in
110 days
<> Below is a summary of updates to the BioMedReports.com FDA Calendar , which includes a database of 265 entries as of 7/21/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com <> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-stage clinica>>...
|
Updated FDA, Clinical Trial Calendars: AZN, MYGN, NVS, PSDV
NVS
|
|
|
+17.87%
in
104 days
(closed on 07/21/09)
<> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 113 entries through 4/8/09. The FDA Calendar includes the following information: company name, ticker, decision >...
|
A Resurgence in Cell Therapeutics
NVS
|
|
|
-3.12%
in
6 days
(closed on 04/08/09)
Since I profiled Cell Therapeutics (CTIC) two months ago as a cancer biotech that was down, but not out; the stock price has more than quadrupled from 8 cents to 36 cents during intraday trading today. CTIC continues to reduce operating expenses and sold its remaining stake in a joint venture to market cancer drug Zevalin to Spectrum Pharma (SPPI) for $16.5M last month (in addition to receiving $15M last December from SPPI for the initial 50% stake). <> CTIC reduced operating expenses in 2008 by 33% and prov>...
|
Updated Clinical Trial and FDA Decision Calendars
NVS
|
|
|
+4.88%
in
18 days
(closed on 04/02/09)
<> <> Below is a summary of updates to the www.BioMedReports.com database of 242 entries included in the FDA and Clinical Trial Calendars. The two web links below are for the FDA calendar home page and a recent article highlighting 14 extreme trades of companies with market caps below $200M with pending FDA decisions. http://biomedreports <wbr> </wbr> .com/fda-calendar.ht <wbr> </wbr> ml http://biomedreports <wbr> </wbr> .com/articles/most-p <wbr> </wbr> opular/627-trading-f <wbr> </wbr> da-decisions-14-extr <wbr> </wbr> eme-trades.html The FDA Calenda>>...
|
Momenta Pharma's Three-Part Strategy
NVS
|
|
|
+3.59%
in
9 days
(closed on 03/15/09)
Momenta Pharma (MNTA) is pursuing a three-part business model which includes complex generic equivalents in partnership with the Sandoz division of Novartis (NVS), proprietary compounds, and follow-on- biologics (FOB). <> Momenta is partnered with Sandoz to develop a generic equivalent (M-Enoxaparin) of the multi-billion dollar injectable blood thinner Lovenox ($3.9B in worldwide sales for 2008). While MNTA + NVS were not the first to file for a generic version of Lovenox, the 180-day exclusivity period awarded to the first-to-file company is set to expire on 4/1/09 for Amphasta>...
|
From the Blogosphere
Lower Q3 Loss for Human Genome – Analyst Blog
|
|
|
Human Genome Sciences, Inc. (HGSI) reported third quarter net loss of $49 million or 32 cents per share, in-line with the Zacks Consensus Estimate. The company reported a net loss of $74.2 million or 50 cents in the year ago quarter. The lower net loss for the quarter was primarily attributable to increased revenues from manufacturing and development services and lower operating expenses.
Revenues for the quarter came in at $18.834 million which reflected an increase of 60.6%. Revenues were inclusive of $8.7 million from manufacturing and development services, $8.9 million recognized under...
|
Titan Pharma Stock Remains Primed to Spike
<>Titan Pharmaceuticals (TTNP.PK) was mentioned in a weekend article by the Washington Post that highlighted the CEO of Vanda Pharmaceuticals, Mihael Polymeropoulos, and Fanapt - Vanda's recently approved drug to treat schizophrenia of which Titan will reap up to 10% in royalties.
While Novartis (NVS) emerged as Vanda's partner to commercialize the product, it's long been my speculation that Titan will eventually be gobbled up by a larger company, and the following comment by Titan CEO Sunil Bhonsle in the Post article does nothing to stave off my speculation: <>"There tends to be a pattern wher>>...
|
Alcon Delivers, Moves Ever Closer to $181
Back in August, I advised investors to load up on Alcon (ACL), the eye care company because, this New Year's, Novartis (NVS) could be forced to buy all of Nestle's (NSRGY.PK) approximately 150 million at a $181 price. In brief, Nestle's has the right as of January 1 to sell all of its 52% share of Alcon to Novartis for 20.5% above the average of the past week price to a maximum of $181. I speculated that minority shareholders could piggyback on the ride to $181.
|
Where should granny put $50,000?
NVS
|
|
|
+4.89%
in
30 days
Filed under: Getting started, McDonald's (MCD), Diageo plc (DEO), Johnson and Johnson (JNJ), Altria Group (MO), Novartis AG ADS (NVS), Automatic Data Proc (ADP), Kellogg Co (K), Consolidated Edison (ED), General Mills (GIS), Procter and Gamble (PG), Merck and Co (MRK), Duke Energy (DUK), Personal finance, S and P 500, Stocks to Buy, Southern Company (SO), Annaly Capital Management (NLY) <> One of my wonderful friends, Ms. P, asked me for some guidance on how she might allocate $50,000 currently earning peanuts in a money market account. Though she is decades from becoming a grandmother, after a>...
|
Analyst upgrades, downgrades and initiations: CBRL, GAME, LO, NKE, RAIL, TGT, WMT ...
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Visit streetinsider.com
Be the first to start a discussion and earn 2 points.
More Resources
|